CHUTIMA NINGSOMBOON: Open Payments
NPI 1124057831 · GRANADA HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,166 in 42 payments from 16 companies in 2025. Trend: 2023 $1,445 · 2024 $1,057 · 2025 $1,166
Food & beverage: $1,166
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 6 | $240 |
| Novartis Pharmaceuticals Corporation | 4 | $159 |
| Incyte Corporation | 6 | $152 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 5 | $134 |
| GENZYME CORPORATION | 3 | $116 |
| LEO Pharma Inc. | 4 | $89 |
| Lilly USA, LLC | 3 | $66 |
| UCB, Inc. | 2 | $58 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $29 |
Products named: DUPIXENT, OPZELURA, ILUMYA, Winlevi, Bimzelx, TALTZ, ANZUPGO, ADBRY.
Industry payments across CA — which companies pay providers there.
